Srividya Velagapudi,Gergely Karsai,Maria Karsai,Shafeeq A Mohammed,Fabrizio Montecucco,Luca Liberale,Hwan Lee,Federico Carbone,Giovanni Francesco Adami,Kangmin Yang,Margot Crucet,Sokrates Stein,Franceso Paneni,Tetiana Lapikova-Bryhinska,Hyun-Duk Jang,Simon Kraler,Daria Vdovenko,Richard Arnold Züllig,Giovanni G Camici,Hyo-Soo Kim,Reijo Laaksonen,Philipp A Gerber,Thorsten Hornemann,Alexander Akhmedov,Thomas F Lüscher

Abstract:Background Obesity and type 2 diabetes (T2D) are major risk factors for cardiovascular diseases (CVD). Dysregulated pro-apoptotic ceramide synthesis reduces β-cell insulin secretion, thereby promoting hyperglycemic states which may manifest as T2D. Pro-apoptotic ceramides modulate insulin sensitivity and glucose tolerance while being linked to poor cardiovascular outcomes. Sirtuin-1 (SIRT1) is a NAD + - dependent deacetylase that protects against pancreatic β-cell dysfunction; however, systemic levels are decreased in obese T2D mice and may promote pro-apoptotic ceramide synthesis and hyperglycemia. Herein, we aimed to assess the effects of restoring circulating SIRT1 levels to prevent metabolic imbalance in obese and diabetic mice. Methods and Results Circulating SIRT1 levels were reduced in obese diabetic mice (db/db) as compared to age-matched non-diabetic db/+ controls. Restoration of SIRT1 plasma levels with recombinant murine SIRT1 for 4-weeks prevented body weight gain, improved glucose tolerance, insulin sensitivity and vascular function in mice models of obesity and T2D. Untargeted lipidomics revealed that SIRT1 restored insulin-secretory function of β-cells by reducing synthesis and accumulation of pro-apoptotic ceramides. Molecular mechanisms involved direct binding to and deacetylation of Toll-like receptor 4 (TLR4) by SIRT1 in β-cells thereby decreasing the rate limiting enzymes of sphingolipid synthesis SPTLC1/2 via AKT/NF-κB. Among T2D patients, those with high baseline plasma levels of SIRT1 prior to metabolic surgery displayed restored β-cell function (HOMA2- β) and were more likely to have T2D remission during follow-up. Conclusion Acetylation of TLR4 promotes β-cell dysfunction via ceramide synthesis in T2D, which is blunted by systemic SIRT1 replenishment. Hence, restoration of systemic SIRT1 may provide a novel therapeutic strategy to counteract toxic ceramide synthesis and mitigate cardiovascular complications of T2D.

Sirt1-PPARS Cross-Talk in Complex Metabolic Diseases and Inherited Disorders of the One Carbon Metabolism

SIRT1 in metabolic syndrome: where to target matters.

Dual-edged role of SIRT1 in energy metabolism and cardiovascular disease

Novel Role of the SIRT1 in Endocrine and Metabolic Diseases

Peroxisome Proliferator-Activated Receptor Γ Coactivator 1α Maintains NAD+ Bioavailability Protecting Against Steatohepatitis

SIRT1 and Energy Metabolism

Sirtuin 1 regulates the phenotype and functions of dendritic cells through Ido1 pathway in obesity

Effects of SIRT1 on material metabolism and influence factors

Brain SIRT1 Mediates Metabolic Homeostasis and Neuroprotection

SIRT1 promotes lipid metabolism and mitochondrial biogenesis in adipocytes and coordinates adipogenesis by targeting key enzymatic pathways

Activation and inhibition of sirtuins: From bench to bedside

SIRT1 selectively exerts the metabolic protective effects of hepatocyte nicotinamide phosphoribosyltransferase

Sirtuins: Key players in obesity-associated adipose tissue remodeling

SIRT1 Activation by Natural Phytochemicals: An Overview

Diverse Roles of SIRT1 in Cancer Biology and Lipid Metabolism

Hepatic Sirt1 Deficiency in Mice Impairs Mtorc2/akt Signaling and Results in Hyperglycemia, Oxidative Damage, and Insulin Resistance.

Multiple Roles of SIRT2 in Regulating Physiological and Pathological Signal Transduction

Inhibition of de novo ceramide synthesis by Sirtuin-1 improves beta-cell function and glucose metabolism in type 2 diabetes

Sirt1: A Novel Adipocyte and Myocyte Regulatory Factor

A pharmacological review on SIRT 1 and SIRT 2 proteins, activators, and inhibitors: Call for further research

Inhibitory protein–protein interactions of the SIRT1 deacetylase are choreographed by post‐translational modification